Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Rates of myocardial infarction and stroke in patients initiated on SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: results from the CVD-REAL study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Is glucagon-like peptide-1 fully protected by dipeptidyl peptidase 4 inhibitor administration in patients with type 2 diabetes?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cardiovascular biomarkers in clinical studies of type 2 diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  1. Prevalence, incidence and mortality of type 1 and type 2 diabetes in Denmark 1996-2016

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Role of fasting duration and weekday in incretin and glucose regulation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Estimates of prediabetes and undiagnosed type 2 diabetes in Denmark: The end of an epidemic or a diagnostic artefact?

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Mikhail Kosiborod
  • Kåre I Birkeland
  • Matthew A Cavender
  • Alex Z Fu
  • John P Wilding
  • Kamlesh Khunti
  • Reinhard W Holl
  • Anna Norhammar
  • Marit Eika Jørgensen
  • Eric T Wittbrodt
  • Marcus Thuresson
  • Johan Bodegård
  • Niklas Hammar
  • Peter Fenici
  • CVD-REAL Investigators and Study Group
View graph of relations

The multinational, observational CVD-REAL study recently showed that initiation of sodium-glucose co-transporter-2 inhibitors (SGLT-2i) was associated with significantly lower rates of death and heart failure vs. other glucose-lowering drugs (oGLDs). This sub-analysis of CVD-REAL sought to determine the association between initiation of SGLT-2i vs. oGLDs and rates of myocardial infarction (MI) and stroke. Medical records, claims and national registers from the US, Sweden, Norway and Denmark were used to identify patients with T2D newly initiated on SGLT-2i (canagliflozin, dapagliflozin or empagliflozin) or oGLDs. A non-parsimonious propensity score was developed within each country to predict initiation of SGLT-2i, and patients were matched 1:1 in the treatment groups. Pooled hazard ratios (HR) and 95% CI were generated using Cox regression models. Overall, 205,160 patients were included. In the intent-to treat analysis, over 188,551 and 188,678 person-years follow-up (MI and stroke, respectively), there were 1077 MI and 968 stroke events. Initiation of SGLT-2i vs. oGLD was associated with a modestly lower risk of MI and stroke (MI: HR 0.85, 95%CI 0.72-1.00; P=0.05; Stroke: HR 0.83, 95%CI 0.71-0.97; P=0.02). These findings complement the results of the cardiovascular outcomes trials, and offer additional reassurance in regards to the cardiovascular effects of SGLT-2i, specifically as it relates to ischaemic events.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Volume20
Issue number8
Pages (from-to)1983-1987
Number of pages4
ISSN1462-8902
DOIs
Publication statusPublished - Aug 2018

    Research areas

  • Journal Article

ID: 53599497